Spinifex Pharma

Spinifex Pharmaceuticals is a clinical-stage Australian biotechnology company specialising in the development of products for the treatment of pain.

News & Events

27TH MARCH 2013

Spinifex Receives $1.5m in R&D Tax Incentive for Research Activities Related to the Discovery of Treatments for Pain
Read More

30TH JANUARY 2013

Pivotal EMA401 mechanism of action data has now been published in the European Journal of Pain
Read More

10TH DECEMBER 2012

Spinifex Initiates Phase 2 Proof-Of-Concept Clinical Trial in Chemotherapy Induced Neuropathy
Read More

4TH DECEMBER 2012

Spinifex featured in Drug Discovery & Development
Read More

2ND NOVEMBER 2012

Spinifex Pharmaceuticals Presents at the Australasian Life Science Investment 2012
Read More

31ST OCTOBER 2012

Spinifex Feautured in Ahead of the Curve Magazine
Read More

8TH OCTOBER 2012

Imperial academics contribute to novel pain drug success
Read More

28TH AUGUST 2012

Positive Phase 2 Results for EMA401 in Postherpetic Neuralgia
Read More

24TH MAY 2012

Spinifex attending the 2012 BIO International Convention in Boston
Read More

16TH FEBRUARY 2012

Spinifex Wins a BioSpectrum Editor's Choice Award in the Category of 'BioSpectrum Asia-Pacific Emerging Company of the Year 2012'
Read More

10TH JANUARY 2012

Spinifex presented at the Biotech Showcase 2012 conference in San Francisco
Read More

6TH DECEMBER 2011

Appointment of Spinifex Non-Executive Chairman.
Read More

16TH NOVEMBER 2011

Pharma Television interviewed Tom McCarthy, Spinifex CEO, at the Bio-Partnering Europe conference held in London in October 2011.
Read More

1ST NOVEMBER 2011

Spinifex Pharmaceuticals Presented at the BioPartnering Europe, BIO Investor Forum and BIO-Europe Conferences in Late 2011.
Read More

19TH SEPTEMBER 2011

Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Postherpetic Neuralgia
Read More

12TH SEPTEMBER 2011

New Data on EMA401 in Model of Diabetic Neuropathy Presented at the 21st Annual NEURODIAB Meeting
Read More

29TH AUGUST 2011

Spinifex Pharmaceuticals featuring in BioCentury, The Bernstein Report on BioBusiness
Read More

23RD AUGUST 2011

Spinifex Closes AU$18.25M (~US$19M) Expanded Series B Round to Broaden Phase 2 Program
Read More

14TH APRIL 2011

Spinifex Pharmaceuticals featuring in the AusIndustry Innovation Australia Showcase in April 2011
Read More

Latest News & Events

27TH MARCH 2013 Spinifex Receives $1.5m in R&D Tax Incentive for Research Activities Related to the Discovery of ... More

30TH JANUARY 2013 Pivotal EMA401 mechanism of action data has now been published in the European Journal of ... More

10TH DECEMBER 2012 Spinifex Initiates Phase 2 Proof-Of-Concept Clinical Trial in Chemotherapy Induced Neuropathy ... More